Identification of prognostic and bone metastatic alternative splicing signatures in bladder cancer

Bioengineered. 2021 Dec;12(1):5289-5304. doi: 10.1080/21655979.2021.1964252.

Abstract

Bladder cancer (BLCA), originating from the epithelium of the urinary bladder, was the second most common malignancy in the urinary system with a high metastasis rate and poor post-metastasis prognosis. Alternative splicing events (ASEs) were regarded as important markers of tumor progression and prognosis, however, their roles in bladder cancer bone metastasis have not been recognized. In this study, we constructed a predictive model based on ASEs and explored the molecular mechanism of ASEs in BLCA bone metastasis, based on data from the Cancer Genome Atlas (TCGA) and TCGASpliceSeq databases. We proposed the hypothesis that the splicing events of ITGB4 was regulated by the splicing factor JUP, and this regulation might play a key role in BLCA bone metastasis through the glycosphingolipid biosynthesis ganglio series pathway.

Keywords: Alternative splicing; bladder cancer; bone metastasis; prognosis; signaling pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alternative Splicing / genetics*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Bone Neoplasms* / genetics
  • Bone Neoplasms* / secondary
  • Female
  • Humans
  • Male
  • Prognosis
  • Signal Transduction / genetics
  • Transcriptome / genetics
  • Urinary Bladder Neoplasms* / diagnosis
  • Urinary Bladder Neoplasms* / genetics
  • Urinary Bladder Neoplasms* / mortality
  • Urinary Bladder Neoplasms* / pathology

Substances

  • Biomarkers, Tumor

Grants and funding

This study was supported in part by the National Natural Science Foundation of China (Grant No. 81702659; 81772856; 81501203); Youth Fund of Shanghai Municipal Health Planning Commission (No.2017YQ054); Shanghai Municipal Health Commission (Grant No.201940306); Henan medical science and technology research project (Grant No. 201602031).